Journal
BMC NEPHROLOGY
Volume 23, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12882-021-02656-9
Keywords
Nephrotic syndrome; Regorafenib; Thrombotic microangiopathy (TMA); Tyrosine kinase inhibitors (TKI); Case report
Categories
Funding
- 1-3-5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYGD18027]
Ask authors/readers for more resources
This case report and literature review highlight the first reported case of regorafenib-induced TMA and emphasize the rare but life-threatening complications of TKIs in cancer treatment.
Background Regorafenib belongs to a sub-group of small-molecule multi-targeted tyrosine kinase inhibitors(TKIs). In various studies with respect to the side-effect of regorafenib, drug-associated proteinuria standardly qualified to be defined as nephrotic syndrome was rarely reported as well as the relation of regorafenib with the occurrence and development of thrombotic microangiopathy (TMA). Case presentation In this case report and literature review, we presented a 62-year-old patient receiving regorafenib for metastatic colon cancer, manifesting abundant proteinuria, in which TMA was also diagnosed through renal biopsy. As far as we were concerned, this was the first reported in terms of regorafenib-induced TMA confirmed by renal biopsy. Conclusion This case indicates that regorafenib, a kind of TKIs may result in TMA, which is a rare but life-threatening complication of cancer treatment drug. Insights from this case might help physicians diagnose rare forms of TMA and adjust treatment for patients in a timely manner.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available